Welcome to our dedicated page for Apogee Therapeutics news (Ticker: APGE), a resource for investors and traders seeking the latest updates and insights on Apogee Therapeutics stock.
Apogee Therapeutics, Inc. develops novel biologic antibody programs for inflammatory and immunology diseases, with disclosed focus areas including atopic dermatitis, asthma, eosinophilic esophagitis and chronic obstructive pulmonary disease. Its programs target established mechanisms of action and use antibody engineering intended to optimize half-life and dosing properties.
Recurring APGE news includes clinical data and pipeline updates for zumilokibart (APG777), APG279, which combines zumilokibart with APG990, and APG333. Company updates also cover operating and financial results, public equity offerings, management conference participation, shareholder-voting matters, governance changes and financing activity to support preclinical studies, clinical trials, manufacturing, commercial readiness and general corporate purposes.
Apogee Therapeutics (NASDAQ:APGE) announced that data from its Phase 2 APEX trial of APG777 for moderate-to-severe atopic dermatitis will be presented at the EADV Congress 2025 in Paris. The presentation will highlight the drug's 16-week topline data, which successfully met primary and secondary endpoints.
APG777 stands out as the only biologic being tested for 3- and 6-month dosing intervals in maintenance treatment. The company will also present data on APG990 and their combination strategy with APG279, a coformulation designed to inhibit Type 1, Type 2, and Type 3 inflammation, potentially expanding their patient reach.
The presentations include a late-breaker oral session by Dr. Emma Guttman-Yassky and three poster presentations covering the APEX program, APG990's safety profile, and the combination therapy approach.
Apogee Therapeutics (Nasdaq: APGE) has announced its upcoming participation in the Stifel 2025 Virtual Immunology and Inflammation Forum. The company's management team will engage in a fireside chat scheduled for Tuesday, September 16, 2025, at 11:30 a.m. E.T.
Investors and interested parties can access both the live and archived versions of the fireside chat through the News & Events page in the Investors section of Apogee Therapeutics' website.
Apogee Therapeutics (NASDAQ:APGE) reported significant progress in its pipeline and Q2 2025 financial results. The company announced positive 16-week data from APEX Phase 2 Part A trial for APG777, their anti-IL-13 antibody for atopic dermatitis, meeting all primary and secondary endpoints. APG777 demonstrated 71.0% EASI reduction vs. 33.8% for placebo, with potential for 3-6 month maintenance dosing versus current bi-weekly standard.
Key developments include first patient dosing in Phase 1b head-to-head trial of APG279 versus DUPIXENT, accelerated APEX Phase 2 Part B readout to mid-2026, and ongoing progress with APG333. The company maintains a strong financial position with $621.2 million in cash, providing runway into Q1 2028, despite increased R&D expenses of $55.7 million and net loss of $66.1 million for Q2 2025.
Apogee Therapeutics (NASDAQ:APGE) announced positive 16-week data from Phase 2 APEX clinical trial of APG777, its anti-IL-13 antibody for moderate-to-severe atopic dermatitis. The trial achieved all primary and secondary endpoints, with APG777 demonstrating a 71.0% decrease in EASI from baseline at Week 16 and an EASI-75 response rate of 66.9% (42.5% placebo-adjusted), marking the highest efficacy of any biologic in a global study.
The drug showed rapid onset of itch relief and was well-tolerated with a favorable safety profile. Based on exposure-response relationships observed, APEX Part B is testing higher doses with readout accelerated to mid-2026. The company plans to initiate Phase 3 trials in 2026, while also conducting a head-to-head trial of APG279 versus DUPIXENT with results expected in 2H 2026.
Apogee Therapeutics (Nasdaq: APGE) has announced a conference call and webcast scheduled for July 7, 2025, at 8:00 a.m. ET to discuss Part A 16-week data from their Phase 2 APEX trial of APG777 in patients with moderate-to-severe atopic dermatitis.
The clinical-stage biotechnology company, which focuses on developing novel biologics for inflammatory and immunology conditions, will present results for APG777, their candidate targeting atopic dermatitis, asthma, eosinophilic esophagitis (EoE), and chronic obstructive pulmonary disease (COPD). The webcast will be accessible through the company's website, with a replay available after the presentation.
Apogee Therapeutics (NASDAQ: APGE) has announced its upcoming participation in the Jefferies Global Healthcare Conference. The company's management team will engage in a fireside chat scheduled for Thursday, June 5, 2025, at 10:30 a.m. ET. Interested parties can access both live and archived versions of the presentation through the News & Events page in the Investors section of Apogee's website.
Apogee Therapeutics (NASDAQ: APGE) has announced its participation in the upcoming Bank of America Health Care Conference. The company's management team will deliver a presentation on Tuesday, May 13, 2025, at 1:40 p.m. PT / 4:40 p.m. ET. Interested parties can access both the live and archived versions of the presentation through the News & Events page in the Investors section of Apogee Therapeutics' website.
Apogee Therapeutics (NASDAQ: APGE) reported significant pipeline progress and 2024 financial results. The company's Phase 2 APEX clinical trial for APG777 has exceeded enrollment in Part A, with Part B initiated ahead of schedule. Topline Part A 16-week data is expected mid-2025.
Key financial highlights include $731.1 million in cash and equivalents, providing runway into Q1 2028. R&D expenses increased to $167.9 million in 2024 (vs $68.4M in 2023), while G&A expenses rose to $49.0 million (vs $24.6M in 2023). Net loss widened to $182.1 million in 2024 from $84.0 million in 2023.
The company reported positive interim results for APG990, with a 60-day half-life supporting three- and six-month dosing potential. APG279 (APG777 + APG990) head-to-head study versus DUPIXENT is planned, with readout expected in H2 2026. Additional pipeline developments include progress in respiratory indications and positive interim data for APG808.